Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04156893 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RH Genotype Matched RBC Transfusions

Study acronym: RBC
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since May 24, 2024, no change to tracked fieldsv10-v12
  2. Phase: Early Phase 1 to Phase 1/2v9 Show 6 more changesShow less
    • Primary completion date: Dec 2024 to Apr 2029
    • Primary endpoints: 1 to 2
    • Study completion date: Jul 2025 to Oct 2029
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoint revised
    • Study description expanded, about 9 words
  3. Primary completion date: Jul 2023 to Dec 2024
    • Study completion date: Jul 2024 to Jul 2025
    v8
  4. Site contact updatedv7
  5. Re-verified, no change to tracked fieldsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Site contact updated
    • Collaborators: 1 to 2
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2020 to Jan 30, 2020
    • Site details revised
    v4
  3. Start date: Dec 2019 to Feb 2020v3
  4. Study description expanded, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.
Trial Details
NCT Number NCT04156893
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: New York Blood Center, National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Sickle Cells Disease
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov